🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia

Recruitingn/aAges 0 Years - 17 YearsAllUniversity Hospital, Strasbourg, France
NCT07898436 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute leukemia is the most common childhood cancer. Despite advances in targeted therapies and immunotherapies, treatment remains challenging for children with relapsed or refractory acute leukemia, particularly those with KMT2A rearrangements, NPM1 mutations, or NUP98 rearrangements. Menin inhibitors have shown promising antileukemic activity in these molecular subgroups. This French national, multicenter, retrospective observational study will describe the pediatric population treated with menin inhibitors for relapsed or refractory acute leukemia. Clinical and biological data will be collected from the SACHA database for patients treated between February 1, 2020, and July 31, 2026. Approximately 10 patients are expected to be included. The study will describe patient and disease characteristics, treatment administration, safety, and efficacy, including remission status, minimal resid

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with relapsed or refractory acute leukemia eligible for menin inhibitor treatment because of a KMT2A or NUP98 rearrangement or an NPM1 mutation. * Patients who received menin inhibitor treatment under a Temporary Authorization for Use (ATU). * Patients younger than 18 years at the time of acute leukemia diagnosis. * Patients who have not objected to the reuse of their data for scientific research. * Patients whose holders of parental authority have already provided authorization for the reuse of the child's data for scientific research. Exclusion Criteria: * Patients who received a Temporary Authorization for Use (ATU) but did not receive the treatment.
💊

What it tests

  • Not listed
📍

Where

1 site
Service de Pédiatrie 3 - Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg - France
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy